The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The gene CDK2 (UniProt accession P24941) encodes cyclin-dependent kinase 2 in Homo sapiens, a member of the CMGC serine/threonine protein kinase superfamily (pellarin2025cyclindependentproteinkinases pages 2-4). This identity has been confirmed through extensive recent literature demonstrating that human CDK2 is a well-characterized cell cycle regulator with conserved kinase domain structure and cyclin-binding properties (pluta2024cyclin‐dependentkinasesmasters pages 3-5, pellarin2025cyclindependentproteinkinases pages 2-4). The protein functions as described in the UniProt annotation as a catalytically active kinase when bound to cyclin partners, distinguishing it from related but functionally distinct CDK family members.
CDK2 functions as an ATP-dependent serine/threonine protein kinase that catalyzes the phosphotransfer reaction from ATP to hydroxyl groups on serine or threonine residues of protein substrates (chi2020anovellandscape pages 1-2, fagundes2021cyclinecdk2dna pages 1-2). The primary biochemical activity involves transferring the γ-phosphate of ATP to specific S/T residues on target proteins, thereby modulating their activity, stability, localization, or protein-protein interaction capabilities during cell cycle progression (fagundes2021cyclinecdk2dna pages 2-3).
CDK2 requires a multistep activation process to achieve catalytic competence (fagundes2021cyclinecdk2dna pages 2-3, zhang2024cdk2andcdk4 pages 1-2). The kinase is inactive as a monomer and must first bind to regulatory cyclin proteins—principally cyclin E1, cyclin E2, or cyclin A—through an interface between the cyclin box domain of the cyclin and the PSTAIRE helix of CDK2 (fagundes2021cyclinecdk2dna pages 2-3). This interaction induces conformational changes in CDK2 that expose the catalytic site and reorient the activation loop (T-loop). Full catalytic activation subsequently requires phosphorylation of threonine 160 (Thr160) in the activation loop by CDK-activating kinase (CAK), which stabilizes the active kinase conformation (fagundes2021cyclinecdk2dna pages 2-3, pluta2024cyclin‐dependentkinasesmasters pages 3-5).
Recent structural and computational analyses have revealed that CDK2, when activated by cyclin E or cyclin A, adopts a catalytically competent conformation more readily than the related kinase CDK4 (zhang2024cdk2andcdk4 pages 1-2). This difference in conformational dynamics and catalytic efficiency correlates with the distinct cell cycle timing requirements of these kinases—CDK2 mediates the relatively brief G1/S transition and S phase progression, whereas CDK4 operates during the longer G1 phase (zhang2024cdk2andcdk4 pages 1-2).
CDK2 exhibits strict substrate specificity for a proline-directed phosphorylation motif (johnson2023anatlasof pages 1-2, chi2020anovellandscape pages 2-3). Specifically, CDK2 preferentially phosphorylates serine or threonine residues that are immediately followed by proline (S/T-P motif). In a comprehensive in situ phosphorylation study using analog-sensitive CDK2 in isolated nuclei, 156 of 166 CDK2-specific thiophosphopeptides (93%) contained at least one S/T-P site, confirming this strong selectivity (chi2020anovellandscape pages 2-3).
A 2023 kinome-wide substrate specificity atlas that profiled 303 serine/threonine kinases found that CDK2 substrate recognition is shaped by both positive selectivity for specific residues and negative selectivity against charged or other residues at defined positions flanking the phosphorylation site (johnson2023anatlasof pages 1-2). Beyond the core S/T-P motif recognized by the kinase catalytic pocket, substrate recruitment is further enhanced by protein-protein interaction domains on the cyclin partners. For example, cyclin E contains MRAIL and VDCLE regions that facilitate binding to RLX-containing proteins and pocket proteins such as the retinoblastoma (Rb) family members (fagundes2021cyclinecdk2dna pages 2-3).
CDK2 functions primarily in the nucleus, where it carries out the majority of its cell cycle regulatory roles (chi2020anovellandscape pages 1-2, chi2020anovellandscape pages 2-3, fagundes2021cyclinecdk2dna pages 2-3). Nuclear localization is essential for CDK2's ability to phosphorylate key substrates such as the retinoblastoma protein (Rb), E2F transcription factors, and numerous chromatin-associated proteins involved in DNA replication and transcription regulation. The nuclear localization of cyclin E, the primary G1/S activator of CDK2, contributes to maintaining CDK2 in the nuclear compartment during late G1 and S phase (fagundes2021cyclinecdk2dna pages 2-3).
Notably, recent work has identified a regulated shift in cyclin A2-CDK2 localization at the S/G2 transition (fagundes2021cyclinecdk2dna pages 2-3). At this cell cycle stage, cyclin A2 transitions from being exclusively nuclear to appearing in both nuclear and cytoplasmic compartments. Cytoplasmic cyclin A2-CDK2 activates the mitotic kinase PLK1 through phosphorylation of the PLK1 activator Bora, demonstrating that CDK2 can execute distinct functions in different cellular compartments depending on the cell cycle phase and cyclin partner (fagundes2021cyclinecdk2dna pages 2-3).
CDK2 occupies a central position in the cyclin-dependent kinase-retinoblastoma-E2F (CDK-Rb-E2F) pathway that controls commitment to DNA replication and progression through the G1/S transition (rubin2020integratingoldand pages 1-3, kim2022cdk46initiatesrb pages 1-2, hume2020aunifiedmodel pages 1-2, matthews2022cellcyclecontrol pages 1-4). This pathway integrates external mitogenic signals and internal cell cycle checkpoints to determine whether cells enter the cell cycle or exit to quiescence.
During early and mid-G1 phase, mitogenic signaling activates CDK4 and CDK6 in complex with D-type cyclins (rubin2020integratingoldand pages 1-3). CDK4/6-cyclin D complexes initiate phosphorylation of Rb protein, causing partial inactivation that begins to relieve E2F transcriptional repression (kim2022cdk46initiatesrb pages 1-2, rubin2020integratingoldand pages 1-3). As E2F activity increases, it drives transcription of cyclin E genes (CCNE1 and CCNE2), leading to accumulation of cyclin E protein in late G1 (fagundes2021cyclinecdk2dna pages 2-3, fagundes2021cyclinecdk2dna pages 1-2).
Cyclin E then binds to and activates CDK2, forming cyclin E-CDK2 complexes that drive the G1/S transition (kim2022cdk46initiatesrb pages 1-2, fagundes2021cyclinecdk2dna pages 2-3, fagundes2021cyclinecdk2dna pages 1-2). Cyclin E-CDK2 completes hyperphosphorylation of Rb at multiple serine and threonine sites including T373, S795, S807, and S811, fully disrupting Rb-E2F repressive complexes and maximally activating E2F-dependent transcription (janostiak2022understandingretinoblastomaposttranslational pages 2-4, kim2022cdk46initiatesrb pages 1-2). This creates a positive feedback loop: active CDK2 drives stronger E2F activity, which promotes further cyclin E and cyclin A expression, sustaining and amplifying CDK2 activity (kim2022cdk46initiatesrb pages 1-2, rubin2020integratingoldand pages 1-3).
Recent single-cell studies have substantially revised the classical irreversible "restriction point" model of G1/S control (cornwell2023lossofcdk46 pages 1-2, kim2022cdk46initiatesrb pages 1-2). Contrary to the long-held view that CDK2 activation creates an autonomous, mitogen-independent feedback loop, new evidence demonstrates that CDK2 activity and Rb phosphorylation depend on continuous upstream mitogen signaling and CDK4/6 activity throughout interphase, not just at the G1/S boundary (cornwell2023lossofcdk46 pages 1-2). When mitogens are removed or CDK4/6 is inhibited, even cells in S or G2 phase can lose CDK2 activity and undergo cell cycle exit with dephosphorylated Rb, indicating that the decision to proliferate remains reversible until cells complete mitosis (cornwell2023lossofcdk46 pages 1-2). These findings reveal that CDK2 functions as a phase-specific amplifier and executor of the proliferative decision rather than an autonomous switch, and that maintenance of CDK2 activity requires continued support from the upstream mitogenic pathway (rubin2020integratingoldand pages 1-3, cornwell2023lossofcdk46 pages 1-2, matthews2022cellcyclecontrol pages 1-4).
Beyond Rb phosphorylation and E2F activation, cyclin E-CDK2 and cyclin A-CDK2 complexes directly regulate the DNA replication machinery (fagundes2021cyclinecdk2dna pages 2-3, fagundes2021cyclinecdk2dna pages 1-2). CDK2 phosphorylates components of the pre-replication complex, including CDC6 and other licensing factors, facilitating the initiation of DNA replication at origins (fagundes2021cyclinecdk2dna pages 2-3). During S phase, cyclin A replaces cyclin E as the predominant CDK2 partner, and cyclin A-CDK2 activity coordinates S phase progression, ensuring proper timing of replication events and preventing re-replication (fagundes2021cyclinecdk2dna pages 2-3, fagundes2021cyclinecdk2dna pages 1-2).
CDK2 also regulates histone biosynthesis to support chromatin assembly during DNA replication. It phosphorylates NPAT (nuclear protein, coactivator of histone transcription) and HIRA, proteins involved in the transcription and processing of replication-dependent histones, thereby coupling histone production to the S phase program (fagundes2021cyclinecdk2dna pages 2-3).
The retinoblastoma tumor suppressor protein (Rb, encoded by RB1) is the canonical and best-characterized substrate of CDK2 (janostiak2022understandingretinoblastomaposttranslational pages 2-4, kim2022cdk46initiatesrb pages 1-2, hume2020aunifiedmodel pages 1-2). CDK2 phosphorylates Rb at multiple sites, with extensively validated sites including T373, S795, S807, and S811 (janostiak2022understandingretinoblastomaposttranslational pages 2-4). Phosphorylation of these residues disrupts the interaction between Rb and E2F transcription factors, converting Rb from a transcriptional repressor to an inactive state and enabling E2F-driven gene expression programs essential for S phase entry and progression (janostiak2022understandingretinoblastomaposttranslational pages 2-4, kim2022cdk46initiatesrb pages 1-2). The extent and pattern of Rb phosphorylation—moving from monophosphorylated forms in early G1 to hyperphosphorylated forms in late G1 and S phase—serve as molecular markers of cell cycle position and commitment (hume2020aunifiedmodel pages 1-2).
CDK2 phosphorylates members of the Cip/Kip family of CDK inhibitors, particularly p27KIP1 (fagundes2021cyclinecdk2dna pages 2-3). Phosphorylation of p27 by cyclin E-CDK2 promotes p27 degradation and contributes to the progressive increase in CDK2 activity during late G1, creating another positive feedback mechanism that reinforces commitment to S phase entry (fagundes2021cyclinecdk2dna pages 2-3).
CDK2 regulates transcriptional programs by phosphorylating transcription factors and coactivators beyond the Rb-E2F axis. Validated substrates include E2F5, which is directly phosphorylated by CDK2, and CBP/p300, transcriptional coactivators whose phosphorylation modulates chromatin accessibility and gene expression (fagundes2021cyclinecdk2dna pages 2-3).
CDK2 substrates involved in DNA replication include CDC6, a component of the pre-replication complex, and CDC25A, a phosphatase that further amplifies CDK activity (fagundes2021cyclinecdk2dna pages 2-3). For histone regulation, CDK2 phosphorylates NPAT, the master regulator of replication-dependent histone gene transcription, thereby ensuring coordinated histone synthesis during S phase (fagundes2021cyclinecdk2dna pages 2-3).
CDK2 controls centrosome duplication by phosphorylating centrosome-associated proteins including nucleophosmin (NPM), CP110, and MPS1 (monopolar spindle 1) (fagundes2021cyclinecdk2dna pages 2-3). These phosphorylation events coordinate centrosome duplication with DNA replication, ensuring that cells complete both processes before entering mitosis.
A comprehensive in situ phosphorylation study using analog-sensitive CDK2 in isolated nuclei identified 117 candidate nuclear CDK2 substrates, of which approximately 43% were previously known CDK substrates, providing strong validation of the approach (chi2020anovellandscape pages 1-2, chi2020anovellandscape pages 2-3). Importantly, this study revealed many previously unidentified substrates enriched in chromatin-associated functions, including:
These findings expand CDK2's functional repertoire beyond canonical cell cycle regulation to include direct roles in chromatin modification, transcriptional regulation, DNA repair, and RNA metabolism (chi2020anovellandscape pages 1-2, chi2020anovellandscape pages 2-3). The identification of these chromatin-associated substrates was likely facilitated by the use of physiological nuclear contexts that preserved CDK2's normal regulatory mechanisms and substrate accessibility.
CDK2 activity is positively regulated through multiple interconnected mechanisms (fagundes2021cyclinecdk2dna pages 2-3, kim2022cdk46initiatesrb pages 1-2, rubin2020integratingoldand pages 1-3):
Cyclin accumulation: Mitogenic signaling drives expression of cyclin E and cyclin A through the CDK4/6-Rb-E2F pathway, providing the essential regulatory subunits for CDK2 activation.
Activating phosphorylation: CAK phosphorylates Thr160 in the CDK2 activation loop, which is required for full catalytic activity.
Positive feedback loops: CDK2-mediated phosphorylation of Rb enhances E2F activity, which drives further cyclin E/A expression; CDK2 phosphorylation of p27 promotes its degradation, removing inhibitory constraints.
Upstream pathway support: Recent evidence indicates that sustained CDK4/6 activity is required to maintain CDK2 activation throughout interphase by sequestering CDK inhibitors and sustaining the mitogenic state (cornwell2023lossofcdk46 pages 1-2).
CDK2 is subject to multiple inhibitory mechanisms that prevent premature or inappropriate activation (fagundes2021cyclinecdk2dna pages 2-3, pluta2024cyclin‐dependentkinasesmasters pages 3-5, cornwell2023lossofcdk46 pages 1-2):
Cip/Kip CDK inhibitors: p21CIP1 and p27KIP1 bind to cyclin-CDK2 complexes and block both CAK-mediated activation and substrate phosphorylation.
Cyclin degradation: Cyclin E is targeted for ubiquitin-mediated proteolysis by the SCF^FBW7 E3 ubiquitin ligase complex following phosphorylation at specific CDC phosphodegron sites, leading to rapid CDK2 inactivation as cells complete S phase (fagundes2021cyclinecdk2dna pages 2-3).
Loss of mitogenic support: Withdrawal of mitogens or inhibition of upstream CDK4/6 activity leads to redistribution of Cip/Kip inhibitors to CDK2, collapse of CDK2 activity, and reversal of Rb phosphorylation, demonstrating the conditional nature of CDK2 activation (cornwell2023lossofcdk46 pages 1-2).
Checkpoint-mediated inhibition: DNA damage checkpoint pathways induce p21 expression through p53, inhibiting CDK2 and blocking cell cycle progression until damage is repaired (hume2020aunifiedmodel pages 1-2).
Recent research has substantially refined our understanding of CDK2's role in cell cycle control, moving beyond simple linear pathway models to appreciate the dynamic, context-dependent nature of CDK2 function (rubin2020integratingoldand pages 1-3, cornwell2023lossofcdk46 pages 1-2, matthews2022cellcyclecontrol pages 1-4).
A major conceptual advance is the recognition that catalytic efficiency and activity thresholds, rather than simple biochemical binding specificity, are the primary determinants of how cyclin-CDK2 complexes drive cell cycle progression (zhang2024cdk2andcdk4 pages 1-2, kim2022cdk46initiatesrb pages 1-2). Structural and computational studies have shown that CDK2 is optimized for rapid activation and high catalytic throughput during the brief G1/S transition, contrasting with the slower activation kinetics of CDK4 during the extended G1 phase (zhang2024cdk2andcdk4 pages 1-2).
The 2023 discovery that cell cycle commitment is fully reversible until mitosis, contingent on continuous mitogen signaling and CDK4/6-CDK2 coordination, has fundamentally challenged the restriction point paradigm (cornwell2023lossofcdk46 pages 1-2). This work demonstrates that CDK2 activity depends on sustained upstream support rather than functioning as an autonomous bistable switch, with important implications for understanding cancer cell responses to CDK4/6 inhibitors in clinical use.
High-throughput proteomic approaches have revealed an unexpectedly broad substrate network for CDK2, extending well beyond canonical cell cycle targets to include chromatin modifiers, DNA repair proteins, and transcriptional regulators (johnson2023anatlasof pages 1-2, chi2020anovellandscape pages 1-2, chi2020anovellandscape pages 2-3). These findings suggest that CDK2 coordinates multiple cellular processes—DNA replication, chromatin remodeling, transcription, and genome maintenance—to ensure coordinated S phase progression.
Finally, recent structural studies have provided detailed molecular views of CDK2 activation mechanisms and substrate recognition, including the 2024 cryo-EM structure of the CDK2-cyclin A-CDC25A complex (zhang2024cdk2andcdk4 pages 1-2). These structures are informing the design of more selective CDK2 inhibitors that target allosteric sites or protein-protein interfaces rather than the conserved ATP-binding pocket.
A comprehensive summary of CDK2 properties is provided in the following reference table:
| Property | Summary | Key details / examples | Evidence / citations |
|---|---|---|---|
| Identity verified | Human CDK2 encodes cyclin-dependent kinase 2, a CMGC-family serine/threonine protein kinase that functions in cell-cycle control | Matches UniProt P24941 description: cyclin-dependent kinase 2; activity centered on G1/S and S-phase progression; functions with cyclin partners rather than as a constitutively active kinase (pluta2024cyclin‐dependentkinasesmasters pages 3-5, pellarin2025cyclindependentproteinkinases pages 2-4) | (pluta2024cyclin‐dependentkinasesmasters pages 3-5, pellarin2025cyclindependentproteinkinases pages 2-4) |
| Protein structure and domains | CDK2 has the canonical bilobed protein kinase fold, including the ATP-binding site, PSTAIRE helix, and activation/T-loop that must adopt an active conformation | Cyclin binding reorganizes the kinase conformation; the catalytic site becomes fully competent after activating phosphorylation of Thr160 in the T-loop by CAK; recent structural analyses emphasize conformational tuning of catalytic efficiency in CDK2 versus CDK4 (zhang2024cdk2andcdk4 pages 1-2, fagundes2021cyclinecdk2dna pages 2-3) | (zhang2024cdk2andcdk4 pages 1-2, fagundes2021cyclinecdk2dna pages 2-3) |
| Enzymatic function | CDK2 catalyzes ATP-dependent phosphorylation of serine/threonine residues on protein substrates | Primary biochemical role is phosphotransfer to substrate S/T residues, especially in cell-cycle regulators and chromatin-associated proteins; phosphorylation controls substrate activity, stability, or protein-protein interactions during G1/S and S phase (chi2020anovellandscape pages 1-2, fagundes2021cyclinecdk2dna pages 1-2) | (chi2020anovellandscape pages 1-2, fagundes2021cyclinecdk2dna pages 1-2) |
| Catalytic mechanism | CDK2 is activated in a multistep manner requiring cyclin binding and T-loop phosphorylation | Cyclin E or cyclin A binds CDK2 through the cyclin box/PSTAIRE interface, inducing conformational changes that expose the catalytic site; CAK then phosphorylates Thr160, stabilizing the active kinase state (fagundes2021cyclinecdk2dna pages 2-3, pluta2024cyclin‐dependentkinasesmasters pages 3-5) | (fagundes2021cyclinecdk2dna pages 2-3, pluta2024cyclin‐dependentkinasesmasters pages 3-5) |
| Cyclin partners | Principal activating partners are cyclin E1/E2 and cyclin A | Cyclin E–CDK2 predominates in late G1/G1-S transition; cyclin A–CDK2 acts later in S phase and into G2-associated functions; cyclin E is the main G1 activator and cyclin A sustains later interphase CDK2 activity (chi2020anovellandscape pages 1-2, fagundes2021cyclinecdk2dna pages 1-2, rubin2020integratingoldand pages 1-3) | (chi2020anovellandscape pages 1-2, fagundes2021cyclinecdk2dna pages 1-2, rubin2020integratingoldand pages 1-3) |
| Cell-cycle phases of activity | CDK2 activity peaks across late G1, G1/S transition, and S phase, with cyclin-specific phase usage | Cyclin E/CDK2 promotes S-phase entry; cyclin A/CDK2 coordinates S-phase progression and later interphase events; newer work also indicates CDK2 activity in interphase depends on continued upstream mitogen/CDK4/6 support more than older irreversible models predicted (kim2022cdk46initiatesrb pages 1-2, cornwell2023lossofcdk46 pages 1-2) | (kim2022cdk46initiatesrb pages 1-2, cornwell2023lossofcdk46 pages 1-2) |
| Core pathway role | Central effector in the CDK4/6–Rb–E2F–cyclin E/A–CDK2 pathway controlling commitment to DNA replication | CDK4/6 initiates Rb inactivation and E2F activation; rising CDK2 activity then drives stronger Rb phosphorylation, promotes E2F-dependent transcription, and helps coordinate commitment with G1/S transition (kim2022cdk46initiatesrb pages 1-2, rubin2020integratingoldand pages 1-3, hume2020aunifiedmodel pages 1-2) | (kim2022cdk46initiatesrb pages 1-2, rubin2020integratingoldand pages 1-3, hume2020aunifiedmodel pages 1-2) |
| Substrate specificity motif | CDK2 is a proline-directed kinase with preference for S/T-P phosphoacceptor motifs | In the in situ nuclear substrate screen, 156/166 AS-CDK2-specific thiophosphopeptides (93%) contained at least one S/T-P site; kinome-wide profiling further shows specificity is shaped by both positive residue preference and negative selectivity around the phosphosite (chi2020anovellandscape pages 2-3, johnson2023anatlasof pages 1-2) | (chi2020anovellandscape pages 2-3, johnson2023anatlasof pages 1-2) |
| Cyclin-mediated substrate recognition | Substrate docking is influenced by cyclin features in addition to the catalytic pocket | Cyclin E contains substrate-interaction surfaces including MRAIL and VDCLE regions that help engage RLX-containing proteins and pocket proteins such as RB family members, contributing to substrate selection beyond the kinase active site alone (fagundes2021cyclinecdk2dna pages 2-3) | (fagundes2021cyclinecdk2dna pages 2-3) |
| Major validated substrate: RB1/Rb | Retinoblastoma protein (Rb) is a canonical CDK2 substrate and a key mediator of CDK2-driven cell-cycle progression | Cyclin E/CDK2 contributes to late G1 hyperphosphorylation of Rb, disrupting Rb–E2F repression and promoting transcription of S-phase genes; reported sites include T373, S795, S807/S811 among others (janostiak2022understandingretinoblastomaposttranslational pages 2-4, kim2022cdk46initiatesrb pages 1-2, hume2020aunifiedmodel pages 1-2) | (janostiak2022understandingretinoblastomaposttranslational pages 2-4, kim2022cdk46initiatesrb pages 1-2, hume2020aunifiedmodel pages 1-2) |
| Other validated substrates: CKI/transcription regulators | CDK2 phosphorylates regulators that reinforce proliferation and transcriptional output | Examples summarized in recent reviews include p27KIP1, E2F5, and CBP/p300, linking CDK2 to CKI regulation and transcriptional control (fagundes2021cyclinecdk2dna pages 2-3) | (fagundes2021cyclinecdk2dna pages 2-3) |
| Other validated substrates: replication / histone control | CDK2 directly regulates DNA replication and histone gene expression machinery | Reported substrates include CDC6, NPAT, and HIRA; these support replication origin function and histone biosynthesis needed for S phase (fagundes2021cyclinecdk2dna pages 2-3, fagundes2021cyclinecdk2dna pages 1-2) | (fagundes2021cyclinecdk2dna pages 2-3, fagundes2021cyclinecdk2dna pages 1-2) |
| Other validated substrates: centrosome cycle | CDK2 phosphorylates centrosome-associated proteins important for duplication and cell-cycle coordination | Validated examples include NPM, CP110, and MPS1, supporting centrosome duplication and broader cell-cycle execution (fagundes2021cyclinecdk2dna pages 2-3) | (fagundes2021cyclinecdk2dna pages 2-3) |
| Nuclear substrate landscape | Proteomics identified a broad nuclear CDK2 substrate network beyond classic cell-cycle proteins | An in situ phosphorylation study identified 117 candidate nuclear substrates, with ~43% already known CDK substrates; validated novel targets included LSD1, DOT1L, and Rad54, extending CDK2 function into chromatin, DNA repair, and transcription-linked regulation (chi2020anovellandscape pages 1-2, chi2020anovellandscape pages 2-3) | (chi2020anovellandscape pages 1-2, chi2020anovellandscape pages 2-3) |
| Subcellular localization | CDK2 functions primarily in the nucleus, where it phosphorylates Rb and many chromatin-associated substrates | Nuclear context was important for recovering physiological substrates in isolated nuclei; cyclin E is also described as mainly nuclear; nuclear localization aligns with roles in Rb/E2F control, replication, and histone transcription (chi2020anovellandscape pages 1-2, fagundes2021cyclinecdk2dna pages 2-3) | (chi2020anovellandscape pages 1-2, fagundes2021cyclinecdk2dna pages 2-3) |
| Cytoplasmic/extranuclear function | A subset of CDK2 activity also occurs outside the nucleus in later interphase | At the S/G2 transition, cyclin A2–CDK2 appears in the cytoplasm and can activate PLK1 through Bora phosphorylation, indicating regulated compartment switching for specific downstream outputs (fagundes2021cyclinecdk2dna pages 2-3) | (fagundes2021cyclinecdk2dna pages 2-3) |
| Positive regulation | CDK2 is positively regulated by cyclin accumulation, CAK, mitogen-driven upstream signaling, and Rb/E2F feedback | Mitogenic signaling induces cyclin D then E2F, leading to cyclin E accumulation and CDK2 activation; CAK phosphorylation of Thr160 is required for full activity; increasing CDK2 activity helps establish the Rb/E2F positive-feedback module before DNA replication (kim2022cdk46initiatesrb pages 1-2, fagundes2021cyclinecdk2dna pages 2-3, rubin2020integratingoldand pages 1-3) | (kim2022cdk46initiatesrb pages 1-2, fagundes2021cyclinecdk2dna pages 2-3, rubin2020integratingoldand pages 1-3) |
| Negative regulation | CDK2 is restrained by p21CIP1, p27KIP1, inhibitory phosphorylation pathways, and loss of mitogenic support | Cip/Kip proteins inhibit cyclin-CDK2 complexes and limit CAK access/substrate engagement; broader CDK control also involves inhibitory phosphorylation and phosphatase circuits; recent work shows CDK2 activity can collapse when mitogen/CDK4/6 support is lost, even outside G1 (pluta2024cyclin‐dependentkinasesmasters pages 3-5, fagundes2021cyclinecdk2dna pages 2-3, cornwell2023lossofcdk46 pages 1-2) | (pluta2024cyclin‐dependentkinasesmasters pages 3-5, fagundes2021cyclinecdk2dna pages 2-3, cornwell2023lossofcdk46 pages 1-2) |
| Current expert view | Modern models treat CDK2 as a phase-specific amplifier and executor of G1/S commitment rather than a simple redundant kinase | Reviews and recent single-cell studies support a model in which CDK2 integrates upstream mitogenic state, Rb/E2F feedback, and replication-entry machinery; it is especially important for the timing and threshold of commitment to DNA replication (rubin2020integratingoldand pages 1-3, kim2022cdk46initiatesrb pages 1-2, cornwell2023lossofcdk46 pages 1-2, matthews2022cellcyclecontrol pages 1-4) | (rubin2020integratingoldand pages 1-3, kim2022cdk46initiatesrb pages 1-2, cornwell2023lossofcdk46 pages 1-2, matthews2022cellcyclecontrol pages 1-4) |
Table: This table summarizes the core structural, enzymatic, pathway, localization, and regulatory properties of human CDK2, with emphasis on experimentally supported functions and recent mechanistic interpretations. It is useful as a compact functional annotation reference grounded in the cited literature.
CDK2 (UniProt P24941) is a serine/threonine protein kinase that serves as a central regulator of the mammalian cell cycle, specifically controlling the G1/S transition and S phase progression through coordinated phosphorylation of a broad network of substrates. The primary enzymatic function is ATP-dependent phosphorylation of serine/threonine residues in proline-directed (S/T-P) motifs on substrate proteins. CDK2 requires binding to cyclin E or cyclin A regulatory subunits and activating phosphorylation at Thr160 for full catalytic activity.
The protein functions predominantly in the nucleus, where it phosphorylates key substrates including the retinoblastoma protein (Rb), CDK inhibitors, transcription factors, DNA replication machinery components, histone regulatory proteins, and chromatin-associated factors. Through these substrates, CDK2 executes critical roles in the CDK-Rb-E2F pathway, drives S phase entry and progression, coordinates DNA replication with histone biosynthesis and centrosome duplication, and links cell cycle progression to chromatin regulation and DNA repair.
Recent evidence has substantially revised classical models of CDK2 function, demonstrating that CDK2 activity is maintained by continuous upstream mitogen and CDK4/6 support rather than functioning as an autonomous feedback loop, that cell cycle commitment remains reversible until mitosis, and that CDK2 regulates a much broader substrate network than previously appreciated. These findings establish CDK2 as a context-dependent amplifier and executor of the proliferative decision whose activity is finely tuned by catalytic efficiency, substrate accessibility, regulatory feedback loops, and integration with upstream signaling pathways.
References
(pellarin2025cyclindependentproteinkinases pages 2-4): Ilenia Pellarin, Alessandra Dall'Acqua, Andrea Favero, I. Segatto, Valentina Rossi, Nicole Crestan, Javad Karimbayli, B. Belletti, and Gustavo Baldassarre. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduction and Targeted Therapy, Jan 2025. URL: https://doi.org/10.1038/s41392-024-02080-z, doi:10.1038/s41392-024-02080-z. This article has 323 citations and is from a peer-reviewed journal.
(pluta2024cyclin‐dependentkinasesmasters pages 3-5): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. Wiley Interdisciplinary Reviews. RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 57 citations and is from a peer-reviewed journal.
(chi2020anovellandscape pages 1-2): Yong Chi, John H. Carter, Jherek Swanger, Alexander V. Mazin, Robert L. Moritz, and Bruce E. Clurman. A novel landscape of nuclear human cdk2 substrates revealed by in situ phosphorylation. Science Advances, Apr 2020. URL: https://doi.org/10.1126/sciadv.aaz9899, doi:10.1126/sciadv.aaz9899. This article has 47 citations and is from a highest quality peer-reviewed journal.
(fagundes2021cyclinecdk2dna pages 1-2): Rafaela Fagundes and Leonardo K. Teixeira. Cyclin e/cdk2: dna replication, replication stress and genomic instability. Frontiers in Cell and Developmental Biology, Nov 2021. URL: https://doi.org/10.3389/fcell.2021.774845, doi:10.3389/fcell.2021.774845. This article has 311 citations.
(fagundes2021cyclinecdk2dna pages 2-3): Rafaela Fagundes and Leonardo K. Teixeira. Cyclin e/cdk2: dna replication, replication stress and genomic instability. Frontiers in Cell and Developmental Biology, Nov 2021. URL: https://doi.org/10.3389/fcell.2021.774845, doi:10.3389/fcell.2021.774845. This article has 311 citations.
(zhang2024cdk2andcdk4 pages 1-2): Wengang Zhang, Yonglan Liu, Hyunbum Jang, and Ruth Nussinov. Cdk2 and cdk4: cell cycle functions evolve distinct, catalysis-competent conformations, offering drug targets. JACS Au, 4:1911-1927, May 2024. URL: https://doi.org/10.1021/jacsau.4c00138, doi:10.1021/jacsau.4c00138. This article has 38 citations and is from a peer-reviewed journal.
(johnson2023anatlasof pages 1-2): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 763 citations and is from a highest quality peer-reviewed journal.
(chi2020anovellandscape pages 2-3): Yong Chi, John H. Carter, Jherek Swanger, Alexander V. Mazin, Robert L. Moritz, and Bruce E. Clurman. A novel landscape of nuclear human cdk2 substrates revealed by in situ phosphorylation. Science Advances, Apr 2020. URL: https://doi.org/10.1126/sciadv.aaz9899, doi:10.1126/sciadv.aaz9899. This article has 47 citations and is from a highest quality peer-reviewed journal.
(rubin2020integratingoldand pages 1-3): Seth M. Rubin, Julien Sage, and Jan M. Skotheim. Integrating old and new paradigms of g1/s control. Molecular Cell, 80:183-192, Oct 2020. URL: https://doi.org/10.1016/j.molcel.2020.08.020, doi:10.1016/j.molcel.2020.08.020. This article has 323 citations and is from a highest quality peer-reviewed journal.
(kim2022cdk46initiatesrb pages 1-2): Sungsoo Kim, Alessandra Leong, Minah Kim, and Hee Won Yang. Cdk4/6 initiates rb inactivation and cdk2 activity coordinates cell-cycle commitment and g1/s transition. Scientific Reports, Oct 2022. URL: https://doi.org/10.1038/s41598-022-20769-5, doi:10.1038/s41598-022-20769-5. This article has 117 citations and is from a peer-reviewed journal.
(hume2020aunifiedmodel pages 1-2): Samuel Hume, Grigory L Dianov, and Kristijan Ramadan. A unified model for the g1/s cell cycle transition. Nucleic Acids Research, 48:12483-12501, Nov 2020. URL: https://doi.org/10.1093/nar/gkaa1002, doi:10.1093/nar/gkaa1002. This article has 245 citations and is from a highest quality peer-reviewed journal.
(matthews2022cellcyclecontrol pages 1-4): Helen K. Matthews, Cosetta Bertoli, and Robertus A. M. de Bruin. Cell cycle control in cancer. Nature Reviews Molecular Cell Biology, 23:74-88, Sep 2022. URL: https://doi.org/10.1038/s41580-021-00404-3, doi:10.1038/s41580-021-00404-3. This article has 1864 citations and is from a domain leading peer-reviewed journal.
(janostiak2022understandingretinoblastomaposttranslational pages 2-4): Radoslav Janostiak, Ariadna Torres-Sanchez, Francesc Posas, and Eulàlia de Nadal. Understanding retinoblastoma post-translational regulation for the design of targeted cancer therapies. Cancers, 14:1265, Feb 2022. URL: https://doi.org/10.3390/cancers14051265, doi:10.3390/cancers14051265. This article has 43 citations.
(cornwell2023lossofcdk46 pages 1-2): James A. Cornwell, Adrijana Crncec, Marwa M. Afifi, Kristina Tang, Ruhul Amin, and Steven D. Cappell. Loss of cdk4/6 activity in s/g2 phase leads to cell cycle reversal. Nature, 619:363-370, Jul 2023. URL: https://doi.org/10.1038/s41586-023-06274-3, doi:10.1038/s41586-023-06274-3. This article has 103 citations and is from a highest quality peer-reviewed journal.